Krebs Biochemicals & Industries , a prominent player in the biochemical industry, has unveiled its unaudited financial results for the first quarter ended June 30, 2025, alongside significant changes in its leadership structure.

Leadership Transition

The company has announced a major leadership change with the appointment of Manish Kumar Jain as the new Managing Director & CEO. Jain, a Chartered Accountant with over 25 years of experience in Strategic Planning, Finance, and Business Development, will take the helm effective August 7, 2025. His appointment is subject to shareholder approval at the upcoming 33rd Annual General Meeting.

Jain's term as Managing Director & CEO is set for five years, extending until August 6, 2028. He will also serve as an Additional Director on the company's board. This appointment comes as Jitendra Shah steps down from his role as Managing Director & CEO, citing personal reasons. Shah's resignation will take effect from the close of business hours on August 7, 2025.

Board Committee Restructuring

In light of these changes, Krebs Biochemicals has also announced a restructuring of its board committees, effective August 8, 2025. The reconstituted committees are as follows:

Audit Committee

• Chairman: P M Kathariya (Independent Director)
• Members:
  • Dipti Shah (Independent Director)
  • Satya Prakash Chigurupati (Independent Director)
  • Sumanth Karlapudi (Independent Director)
  • Manish Kumar Jain (Managing Director & CEO)

Stakeholder Relationship Committee

• Chairman: Sumanth Karlapudi (Independent Director)
• Members:
  • Dipti Shah (Independent Director)
  • Satya Prakash Chigurupati (Independent Director)
  • P M Kathariya (Independent Director)
  • Manish Kumar Jain (Managing Director & CEO)

Q1 Financial Results

The Board of Directors, in their meeting on August 7, 2025, approved the unaudited financial results for the first quarter ended June 30, 2025. While specific financial figures were not disclosed in the announcement, the company confirmed that these results have undergone a limited review by the company's auditors.

Krebs Biochemicals & Industries continues to demonstrate its commitment to transparency and corporate governance through these timely disclosures and leadership transitions. As the company moves forward under new leadership, stakeholders will be keenly watching how these changes impact the company's strategic direction and financial performance in the coming quarters.

The company's shares are listed on both the BSE and the National Stock Exchange of India.

Krebs Biochemicals & Industries Limited , a prominent player in the biochemical industry, is set to undergo a significant leadership change as Managing Director and CEO Jitendra Shah announces his resignation.

Key Details of the Resignation

• Effective Date: August 7, 2025, at the close of business hours
• Reason: Personal reasons
• Notice Period: Resignation letter submitted on July 25, 2025

Implications for the Company

Jitendra Shah's departure marks a notable shift in Krebs Biochemicals & Industries' top management. Shah, who also held the position of Director, has decided to step down from all his roles within the company. In his resignation letter, Shah expressed gratitude towards the Board Members for their support and confidence during his tenure.

Official Communication

The company has officially informed both the BSE Limited and the National Stock Exchange of India Ltd about this development, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Rakesh R Kalbate, the Company Secretary & Compliance Officer, submitted the formal intimation to the stock exchanges.

Next Steps

As of now, Krebs Biochemicals & Industries Limited has not announced a successor for the Managing Director and CEO position. The company's board is expected to address this transition in the upcoming board meeting scheduled for August 7, 2025.

This leadership change comes at a crucial time for Krebs Biochemicals & Industries, and stakeholders will be keenly watching how the company manages this transition and its potential impact on future strategies and operations.